| Primary |
| Rheumatoid Arthritis |
47.2% |
| Polyarthritis |
11.1% |
| Acute Promyelocytic Leukaemia |
5.6% |
| Atrial Fibrillation |
5.6% |
| Osteoporosis |
5.6% |
| Psoriasis |
5.6% |
| Antibiotic Prophylaxis |
2.8% |
| Coronary Arterial Stent Insertion |
2.8% |
| Gastritis Prophylaxis |
2.8% |
| Psoriatic Arthropathy |
2.8% |
| Sarcoidosis |
2.8% |
| Skin Ulcer |
2.8% |
| Type 2 Diabetes Mellitus |
2.8% |
|
| Post-traumatic Pain |
20.0% |
| Bone Fissure |
10.0% |
| Cytolytic Hepatitis |
10.0% |
| Interstitial Lung Disease |
10.0% |
| Jaundice |
10.0% |
| Lung Infection |
10.0% |
| Pancytopenia |
10.0% |
| Psoriasis |
10.0% |
| Purpura |
10.0% |
|
| Secondary |
| Rheumatoid Arthritis |
51.9% |
| Drug Use For Unknown Indication |
12.3% |
| Psoriatic Arthropathy |
6.2% |
| Psoriasis |
4.3% |
| Product Used For Unknown Indication |
3.7% |
| Ankylosing Spondylitis |
2.9% |
| Pain |
2.7% |
| Hypertension |
2.3% |
| Atrial Fibrillation |
2.0% |
| Hypercholesterolaemia |
1.8% |
| Diabetes Mellitus |
1.7% |
| Lung Infection |
1.7% |
| Systemic Lupus Erythematosus |
1.2% |
| Type 2 Diabetes Mellitus |
1.2% |
| Crohn's Disease |
0.9% |
| Essential Hypertension |
0.8% |
| Acute Promyelocytic Leukaemia |
0.6% |
| Arteritis |
0.6% |
| Dysphagia |
0.6% |
| Hypertriglyceridaemia |
0.6% |
|
| Psoriasis |
10.2% |
| Renal Failure |
9.2% |
| Sinusitis Aspergillus |
9.2% |
| Tuberculosis |
9.2% |
| Thrombocytopenia |
8.2% |
| Interstitial Lung Disease |
7.1% |
| Lung Disorder |
5.1% |
| Pneumonia |
5.1% |
| Weight Decreased |
5.1% |
| Hepatitis |
4.1% |
| Pyrexia |
4.1% |
| Ventricular Tachycardia |
4.1% |
| Drug Ineffective |
3.1% |
| Lymph Node Tuberculosis |
3.1% |
| Prostatitis |
3.1% |
| Agranulocytosis |
2.0% |
| Bladder Cancer |
2.0% |
| Breast Cancer Metastatic |
2.0% |
| Chronic Lymphocytic Leukaemia |
2.0% |
| Cryptococcosis |
2.0% |
|
| Concomitant |
| Rheumatoid Arthritis |
58.6% |
| Drug Use For Unknown Indication |
9.3% |
| Osteoporosis |
5.1% |
| Product Used For Unknown Indication |
3.7% |
| Pain |
2.4% |
| Prophylaxis |
2.4% |
| Unevaluable Event |
2.1% |
| Depression |
1.6% |
| Back Pain |
1.4% |
| Ischaemic Cardiomyopathy |
1.4% |
| Osteoporosis Prophylaxis |
1.4% |
| Psoriasis |
1.4% |
| Psoriatic Arthropathy |
1.4% |
| Convulsion |
1.2% |
| Hypertension |
1.2% |
| Hypothyroidism |
1.2% |
| Ankylosing Spondylitis |
1.0% |
| Hypokalaemia |
1.0% |
| Implant Site Thrombosis |
1.0% |
| Muscle Spasms |
1.0% |
|
| Lung Disorder |
7.7% |
| Metastases To Breast |
7.7% |
| Pulmonary Hypertension |
7.7% |
| Systemic Lupus Erythematosus |
7.7% |
| Transient Ischaemic Attack |
7.7% |
| Pyrexia |
6.4% |
| Spinal Fracture |
6.4% |
| Cognitive Disorder |
5.1% |
| Weight Decreased |
5.1% |
| Myocardial Infarction |
3.8% |
| Non-hodgkin's Lymphoma |
3.8% |
| Paraesthesia |
3.8% |
| Pharyngeal Oedema |
3.8% |
| Prothrombin Level Decreased |
3.8% |
| Transaminases Increased |
3.8% |
| Urinary Tract Infection |
3.8% |
| Vomiting |
3.8% |
| Dyskinesia |
2.6% |
| Erythema Nodosum |
2.6% |
| Lung Neoplasm Malignant |
2.6% |
|
| Interacting |
| Rheumatoid Arthritis |
55.0% |
| Lung Infection |
40.0% |
| Osteoporosis |
5.0% |
|
| Renal Failure Chronic |
40.0% |
| Thrombocytopenia |
40.0% |
| Drug Interaction |
20.0% |
|
